Almac and DSM Pharma sharing enzyme expertise

The two firms are collaborating to improve their green performance and enzyme process development.

Almac has announced that its collaboration agreement with custom manufacturing business DSM Pharmaceutical Products continues to reap success for both companies.

Signed in October 2012, the deal sees the companies working together in the sphere of biocatalysis to provide sustainable manufacturing services to the pharmaceuticals industry.

As per the terms of the collaboration, both parties have access to each other’s enzyme platform technologies, services and expertise for the creation of active pharmaceutical ingredients (APIs).

They have already worked together to share enzyme screening and process development techniques.
While Almac is bringing expertise in rapid enzyme identification to the table, DSM has seen through over 30 different commercial manufacturing bioprocesses on a large scale. The collaboration also enables both companies to improve their green credentials.

Dr. Tom Moody, Head of Almac Biocatalysis, said: “The success of the projects undertaken between Almac and DSM already demonstrates there is a market for scalable green technologies to access difficult-to-make chiral chemicals.

“Cost remains a prevalent issue within the industry and the introduction of enzymes into processes earlier in the drug discovery pipeline helps to drive cost down as projects move forward.”